TherapeuticsMD, Inc.
TXMDHealthcare|Drug Manufacturers - Specialty & Generic|US
$1.74
+0.03 (+1.75%)
Tangible Book / Share
$2.04
Cash / Share
$0.79
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02019589 A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea | Secondary Amenorrhea | P3 | Terminated | 6 | RCT, Double-blind | Progesterone, Placebo |
| NCT02253173 Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women | Vulvovaginal Atrophy, Menopause | P3 | Completed | 764 | RCT, Double-blind | Estradiol, Placebo |
| NCT02224313 Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women | Menopause | P3 | Completed | 20 | Double-blind | oral estradiol 1.0 mg, oral progesterone 100 mg |
| NCT01942668 A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms | Menopause | P3 | Completed | 1,845 | RCT, Double-blind | Estradiol, Progesterone, Placebo |
| NCT02449902 TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy | Menopause, Vulvovaginal Atrophy | P2 | Completed | 50 | RCT, Double-blind | Estradiol, placebo |
| NCT04272008 The Effects of Annovera™ and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol | Contraception | P1 | Completed | 21 | RCT, Open-label | Segesterone Acetate and Ethinyl Estradiol |
| NCT04290390 Annovera™ Drug-Drug Interaction Study | Women, Contraception | P1 | Completed | 67 | RCT, Open-label | Segesterone Acetate and Ethinyl Estradiol, Rifampin, Itraconazole |